Texas Permanent School Fund Raises Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Texas Permanent School Fund boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYGet Rating) by 3.0% in the second quarter, HoldingsChannel reports. The institutional investor owned 16,645 shares of the company’s stock after purchasing an additional 478 shares during the quarter. Texas Permanent School Fund’s holdings in Harmony Biosciences were worth $812,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Catalyst Capital Advisors LLC bought a new position in shares of Harmony Biosciences during the 1st quarter valued at about $27,000. Comerica Bank boosted its holdings in shares of Harmony Biosciences by 3.8% during the 1st quarter. Comerica Bank now owns 19,507 shares of the company’s stock valued at $1,016,000 after purchasing an additional 710 shares during the last quarter. Yousif Capital Management LLC boosted its holdings in shares of Harmony Biosciences by 3.5% during the 1st quarter. Yousif Capital Management LLC now owns 20,879 shares of the company’s stock valued at $1,016,000 after purchasing an additional 710 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Harmony Biosciences by 8.2% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 9,630 shares of the company’s stock valued at $468,000 after purchasing an additional 730 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Harmony Biosciences by 69.7% in the 1st quarter. Acadian Asset Management LLC now owns 3,367 shares of the company’s stock valued at $163,000 after acquiring an additional 1,383 shares during the last quarter. Hedge funds and other institutional investors own 81.24% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on HRMY shares. Mizuho increased their price target on shares of Harmony Biosciences from $60.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, November 8th. Janney Montgomery Scott raised shares of Harmony Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $57.00 to $61.00 in a report on Friday, October 14th. TheStreet raised shares of Harmony Biosciences from a “c” rating to a “b-” rating in a report on Thursday, August 18th. Oppenheimer increased their price target on shares of Harmony Biosciences from $62.00 to $67.00 and gave the company an “outperform” rating in a report on Wednesday, August 3rd. Finally, The Goldman Sachs Group decreased their price objective on shares of Harmony Biosciences from $58.00 to $51.00 and set a “neutral” rating for the company in a research note on Friday, October 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $62.50.

Harmony Biosciences Stock Performance

Shares of NASDAQ:HRMY opened at $57.01 on Monday. The firm has a market cap of $3.38 billion, a PE ratio of 22.27 and a beta of 0.52. The firm’s 50 day simple moving average is $50.10 and its 200-day simple moving average is $48.12. Harmony Biosciences Holdings, Inc. has a one year low of $31.54 and a one year high of $61.55. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.52 and a current ratio of 3.56.

Harmony Biosciences (NASDAQ:HRMYGet Rating) last issued its earnings results on Tuesday, November 1st. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.85. The business had revenue of $117.21 million for the quarter, compared to analyst estimates of $113.11 million. Harmony Biosciences had a net margin of 38.84% and a return on equity of 62.83%. As a group, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.7 EPS for the current year.

Insider Transactions at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 12,173 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $44.68, for a total transaction of $543,889.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Jack Nielsen sold 58,667 shares of Harmony Biosciences stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $58.70, for a total transaction of $3,443,752.90. Following the transaction, the director now directly owns 2,954,794 shares of the company’s stock, valued at $173,446,407.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jeffrey Dierks sold 12,173 shares of Harmony Biosciences stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $44.68, for a total transaction of $543,889.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 522,573 shares of company stock valued at $30,593,896. 34.70% of the stock is currently owned by company insiders.

Harmony Biosciences Profile

(Get Rating)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Further Reading

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYGet Rating).

Institutional Ownership by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.